Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

중증 혈우병 항체 환자에서 시행한 말초삽입 중심혈관 카테터의 유용성

Availability of peripheral inserted central catheters in severe hemophilia patients with inhibitors

  • 박영실 (경희대학교 의과대학 동서신의학병원 소아청소년과)
  • Park, Youngshil (Department of Pediatrics, East-West Neo Medical Center, College of Medicine, Kyung Hee University)
  • 투고 : 2008.10.10
  • 심사 : 2008.10.25
  • 발행 : 2008.12.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

혈우병 환자에서 가장 효과적인 치료 방침은 응고 인자의 보충으로, 그를 위해 안전하고 오래 사용할 수 있는 정맥 확보가 필요하다. 그러나 중심 정맥으로의 port는 전신 마취와 일정한 입원이 필요하고, 혈우병 환자에서 시행할 경우 보험 삭감의 문제도 있다. 본 저자는 두 명의 중증 혈우병 항체 환자에게 말초 삽입 중심 정맥관을 삽입하였다. 환자들은 잦은 출혈 소견 때문에 응고 인자를 투여 받았으며, 그로 인하여 혈관 확보에 어려움이 있었다. 환자 나이는 7세와 11세였다. 제 8 응고 인자 활성도는 모두 1% 이하였으며, 제 8 응고 인자 항체 수치는 각각 160과 26.3 BU/mL였다. 말초 삽입 중심 정맥관은 초음파 인도 하에, 외래에서, 국소 마취로 쉽게 삽입되었다. 말초 삽입 중심 정맥관 삽입은 잦은 출혈을 보이는 혈우병 환자에게 사용해 볼 수 있는 방법이다.

The most effective treatment strategy for patients with hemophilia is replacement therapy with FVIII or FIX concentrates, which usually requires long-term, uncomplicated venous access. However, central venous access device (CVADs, ports) insertion requires inpatient admission and general anesthesia, and presents some problems regarding health insurance coverage. Peripherally inserted central catheters (PICCs) were inserted in two severe hemophilia patients aged 7 and 11 years with high titers of inhibitors. They experienced frequent bleeding episodes and required replacement therapy, which eventually resulted in difficulty in acquiring venous line access. Factor VIII activity was below 1%, and inhibitor titers were 160 and 26.3 BU/ml. In an outpatient setting, PICC lines are easily placed by radiological guidance and require local anesthesia alone. PICC has been feasible, in particular, for hemophilia patients with frequent bleeding episodes.

키워드

참고문헌

  1. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10:134-46 https://doi.org/10.1046/j.1365-2516.2003.00840.x
  2. Parkinson R, Gandhi M, Harper J, Archibald C. Establishing an ultrasound guided peripherally inserted central catheter (PICC) insertion service. Clin Radiol 1998;53:33-6 https://doi.org/10.1016/S0009-9260(98)80031-7
  3. Shaw JCL. Parenteral nutrition in the management of sick low birth weight infants. Pediatr Clin North Am 1973;20: 333-58 https://doi.org/10.1016/S0031-3955(16)32847-4
  4. Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 2005;11:92-9 https://doi.org/10.1111/j.1365-2516.2005.01074.x
  5. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy global progress towards optimal care. Haemophilia 2006;12:75-81
  6. Choi HC, Choe BK, Kim HS, Park WH. Two cases of implantable port insertion in patients with hemophilia. Program and Abstract, the 56th Annual Fall Meeting of the Korean Pediatric Society;2007 Oct 19-05;Seoul. Seoul:The Korean Pediatric Society, 2007:338
  7. Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 2003;9:50-6
  8. Tarantino MD, Lail A, Donfield SM, Lynn H, Peddle L, Hunsberger S, Shapiro AD. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003;9:588-92 https://doi.org/10.1046/j.1365-2516.2003.00793.x
  9. Periard D, Monney P, Waeber G, Zurkinden C, Mazzolai L, Hayoz D, et al. Randomized controlled trial of peripherally inserted central catheters vs. peripheral catheters for middle duration in-hospital intravenous therapy. J Thromb Haemost 2008;6:1281-8 https://doi.org/10.1111/j.1538-7836.2008.03053.x
  10. Thiagarajan RR, Ramamoorthy C, Gettmann T, Bratton SL. Survey of the use of peripherally inserted central venous catheters in children. Pediatrics 1997;99:E4 https://doi.org/10.1542/peds.99.1.4
  11. Abedin S, Kapoor G. Peripherally inserted central venous catheters are a good option for prolonged venous access in children with cancer. Pediatr Blood Cancer 2008;51:251-5 https://doi.org/10.1002/pbc.21344
  12. Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 2002;20:3276-81 https://doi.org/10.1200/JCO.2002.11.135
  13. Chait PG, Ingram J, Phillips-Gordon C, Farrell H, Kuhn C. Peripherally inserted central catheters in children. Radiology 1995;197:775-8 https://doi.org/10.1148/radiology.197.3.7480755
  14. Loughran SC, Borzatta M. Peripherally inserted central catheters:A report of 2506 catheter days. J Parenter Enteral Nutr 1995;19:133-6 https://doi.org/10.1177/0148607195019002133
  15. Lam S, Scannell R, Roessler D, Smith MA. Peripherally inserted central catheters in an acute-care hospital. Arch Intern Med 1994;154:1833-7 https://doi.org/10.1001/archinte.154.16.1833
  16. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007;138:580-6 https://doi.org/10.1111/j.1365-2141.2007.06703.x
  17. Ljung R. Central venous catheters in children with haemophilia. Blood Rev 2004;18:93-100 https://doi.org/10.1016/S0268-960X(03)00043-2
  18. Ewenstein BM, Valentino LA, Journeycake JM, Tarantino MD, Shapiro AD, Blanchette VS, et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004;10:629-48 https://doi.org/10.1111/j.1365-2516.2004.00943.x
  19. Dunn AL, Abshire TC. Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy. Pediatr Blood Cancer 2008;50:627-9 https://doi.org/10.1002/pbc.21095